Share on StockTwits

RBC Capital decreased their target price on shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) from $32.00 to $28.00 in a research note issued on Friday. The firm currently has an “outperform” rating on the stock. RBC Capital’s price objective would suggest a potential upside of 56.25% from the stock’s previous close.

A number of other firms have also recently commented on AUXL. Analysts at Aegis cut their price target on shares of Auxilium Pharmaceuticals to $34.00 in a research note on Thursday. They noted that the move was a valuation call. Finally, analysts at MKM Partners upgraded shares of Auxilium Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Wednesday, May 28th. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $26.92.

Auxilium Pharmaceuticals (NASDAQ:AUXL) opened at 17.92 on Friday. Auxilium Pharmaceuticals has a 1-year low of $16.36 and a 1-year high of $32.89. The stock’s 50-day moving average is $19.94 and its 200-day moving average is $23.95. The company’s market cap is $900.2 million.

Auxilium Pharmaceuticals (NASDAQ:AUXL) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.44) EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.64 by $2.08. The company had revenue of $83.00 million for the quarter, compared to the consensus estimate of $482.80 million. During the same quarter in the prior year, the company posted $0.22 earnings per share. The company’s quarterly revenue was down 17.4% on a year-over-year basis. On average, analysts predict that Auxilium Pharmaceuticals will post $-0.20 earnings per share for the current fiscal year.

Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.

Receive News & Ratings for Auxilium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxilium Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.